Lipoteichoic acid from Staphylococcus aureus increases matrix metalloproteinase 9 expression in RAW 264.7 macrophages: modulation by A2A and A2B adenosine receptors.
Peptidoglycan (PEG) and lipoteichoic acid (LTA) are the main constituents of Gram-positive bacteria cell wall and are described to modulate immune functions. Increased levels of matrix metalloproteinases (MMPs) were described in endotoxemia, suggesting that they participate to tecidual damage, multiple organs failure and vascular disfunction. Staphylococcus aureus PEG is described to increase MMPs 2 and 9 levels in plasma from rat and MMP 9 secretion by human neutrophils, however, the effect of LTA on MMPs is unknown. In this work, was evaluated the modulation of MMPs 2 and 9 expression and secretion in RAW 264.7 macrophages by LTA from S. aureus. The role of A2A and A2B adenosine receptors was also investigated. LTA increased MMP 9 expression and secretion at 12h of treatment. The modulation of MMP 9 secretion was dose dependent, with maximal effect above 1microg/ml. The inhibitor of mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway (U0126, 10microM) prevented LTA stimulation of MMP 9 secretion; however, the inhibitors of p38 (SB203580, 10microM) and Jun N-terminal kinase (JNK; SP600125, 10microM) presented any effect. A2A and A2B adenosine receptors pharmacological blockade or gene knockdown resulted in exacerbated MMP 9 secretion, while an adenosine receptors agonist inhibited LTA-stimulated MMP 9 secretion. These results suggest that LTA increased MMP 9 secretion in macrophages could be involved in complications associated to S. aureus infections. Moreover, LTA modulation of MMP 9 is dependent on MEK/ERK pathway and is regulated by A2A and A2B adenosine receptors.
Souza
Luiz Fernando de
LF
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. lzfsouza@yahoo.com.br
Jardim
Fernanda Rafaela
FR
Sauter
Ismael Pretto
IP
Souza
Marcela Moreira de
MM
Barreto
Fabiano
F
Margis
Rogério
R
Bernard
Elena Aida
EA
D000818:Animals; D002460:Cell Line; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects* / Q000276:immunology; D055785:Gene Knockdown Techniques; D006801:Humans; D008070:Lipopolysaccharides / Q000737:chemistry / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D048670:MAP Kinase Kinase 4 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000276:immunology; D008264:Macrophages / Q000201:enzymology / Q000276:immunology*; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis / Q000276:immunology*; D051379:Mice; D051381:Rats; D043705:Receptor, Adenosine A2A / Q000276:immunology* / Q000378:metabolism; D043704:Receptor, Adenosine A2B / Q000276:immunology* / Q000378:metabolism; D013203:Staphylococcal Infections / Q000201:enzymology / Q000276:immunology*; D013211:Staphylococcus aureus / Q000737:chemistry / Q000276:immunology*; D013682:Teichoic Acids / Q000737:chemistry / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D013997:Time Factors; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism
D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D043705:Receptor, Adenosine A2A; D043704:Receptor, Adenosine A2B; D013682:Teichoic Acids; C009900:lipoteichoic acid; D048051:p38 Mitogen-Activated Protein Kinases; D048670:MAP Kinase Kinase 4; D020780:Matrix Metalloproteinase 9